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Preeclampsia, Genomic Imprinting & Child Neurobehavioral Development: Preeclampsia, a 
hypertensive disorder unique to human pregnancy, is one of the most common and potentially 
modifiable metabolic problems, and affects approximately 10-15% of all pregnancies.1, 2  It is 
defined by the onset of hypertension (140/90 mm HG) after 20 weeks’ gestation in the index 
pregnancy, accompanied by 300 mg of protein in a 24 hour urine specimen, or persistent > 
30mg/dL (1+) protein on a dipstick.2, 3 While the etiology of preeclampsia is still elusive, it 
remains a leading cause of mortality and morbidity among mothers and their babies.3-5 
Recent research has demonstrated that preeclampsia is associated with an increased 
risk for impaired early language development, lower neurocognitive functioning, and ADHD.6-9 
And there is accumulating evidence to show that pregnancy-induced hypertensive disorders, 
especially preeclampsia, can have potentially long-term consequences for the offspring’s 
neurobehavioral development 10, 11  via changes in the epigenome. In recent animal studies, 
genomic imprinting perturbations have been linked to both hypertensive problems and 
neurodevelopmental syndromes.13 Similarly, in humans, adverse pregnancy outcomes have 
been associated with genomic imprinting perturbations, leading to neurodevelopmental 
syndromes14, 15 and subsequent disorders.16, 17 Delineating some of the underlying biological 
mechanisms by which preeclampsia influences the trajectory of optimal/suboptimal child 
development and functioning, can help us in our aim to uncover the mechanisms of 
dysregulated neurobehavioral development and related mental disorders via epigenetic 
changes. 
Severe preeclampsia may cause symptoms such as hypertension, proteinuria, eclampsia, 
cerebral edema, cerebral hemorrhage, long-term neurocognitive dysfunction, blindness, liver 
swelling and other liver damage leading to elevated serum transaminase, oliguria, 
thrombocytopenia, pulmonary edema necrotizing pancreatitis. All of these symptoms can be 
fatal to mothers, and, importantly, to their child in-utero, resulting in greater mortality in 
mothers and varying degrees of child morbidity after birth.2, 18 The main impact of preeclampsia 
on the fetus is malnourishment, resulting from utero-placental vascular insufficiency hypoxia, 
which restricts nutrient supplies and oxygen flow from the placenta to the fetus.19 This leads to 
various perinatal and neonatal problems, including intra-uterine growth restriction (IUGR, 
defined as birth weight less than the 10th percentile),5, 19-25  emergency C-section,5 preterm 
delivery,24, 26, 27 reduced birth weight,5, 28, 29 lower APGAR scores,30 more frequent and 
prolonged neonatal intensive care unit (NICU) stays,5, 20, 31 and increased acute respiratory 
distress syndromes after birth.20, 32 In some cases, fetal damage is so severe that it results in 
fetal demise, such as stillbirth and neonatal death.32, 33  Beyond birth, while the long-term 
health and developmental consequences of exposure to maternal preeclampsia for the 
surviving child are relatively unexplored, there is some evidence for suboptimal neurocognitive 
development among infants with IUGR,34, 35 which is one of the major fetal/child consequences 
of preeclampsia.5, 20-25 Recently, with the leadership of the NICHD, growing efforts have been 
made to find associations between preeclampsia and health consequences in offspring, 
including IUGR,35, 36 preterm birth,37-40 LBW,41-43 and child neurobehavioral development.44-46  
The extent of adverse neurobehavioral and other developmental consequences for 
surviving infants with perinatal problems has been investigated less frequently. Many and 
colleagues (2003), for example, reported that IQ at age 3 years was significantly lower among 
IUGR children with maternal preeclampsia, compared to those without (85.5 vs. 96.9, p=.03).47 
Similarly, Cheng and colleagues (2004) documented that preterm infants of preeclamptic 
mothers, compared to those of non-preeclamptic mothers, had a compromised 
neurodevelopmental index,48 as measured by the Bayley Scales of Infant and Toddler 
Development- Second Edition (Bayley-II).49 Children born to mothers with preeclampsia had a 
lower Mental Developmental Index (MDI) than children born to mothers without at 2 years of 
age (p=.04), while there was no significant difference between the two groups on the Physical 
Developmental Index (PDI) (p=.56). Furthermore, they reported that preeclampsia was 
associated with an over 10-fold increased risk of mildly delayed MDI (p=.007), after controlling 
for demographic and biomedical confounders. Temperament is thought of as an early biological 
characteristic similar to a personality trait. Although it is not typically considered to be a 
neuropsychological construct, there are many overlaps. In particular, the temperamental 
construct of effortful control is very similar to the neuropsychological construct of attention and 
executive functioning.50 More recently, anger and negative emotionality have gained 
considerable attention as temperamental traits that are closely linked to the limbic system in 
the brain.51-53   
Thus, further investigation of the underlying epigenetic mechanisms that show how 
preeclampsia or pregnancy-induced hypertensive problems are associated with early emerging 
temperament profiles of the infant as well as child suboptimal neurodevelopment, using 
validated clinical instruments such as the Early Childhood Behavior Questionnaire (ECBQ),54 and 
the Bayley Scales of Infant and Toddler Development – Third Edition (Bayley-III)49 is warranted. 
 
Placenta Epigenetics and Neurodevelopment:  
The medical condition of the mother affects the nature of in-utero condition (i.e., environment) 
and perturbs gene expression (i.e., genes), which govern the developmental trajectories of 
offspring. When information from these two areas, environment and genes, are examined 
together, they can provide us with important clues as to how the mother’s medical 
complications influence the trajectories of child development.  
 
Over the past decade researchers have begun to consider how the placenta, which is 
usually discarded at birth, could hold important information about the relationship between 
the pre- and perinatal environment and cognitive neurobehavioral outcomes in the developing 
child, over and above the effects of postnatal environment. Many studies have linked poor 
placentation during pregnancy with a wide range of chronic neurodevelopmental disorders in 
children,55-58 including Autism Spectrum Disorder (ASD),59 Attention Deficit Hyperactivity 
Disorder (ADHD)10  and learning disabilities.60 Moreover, recent data from the CDC showed a 
23% increase in identified cases of ASD between 2009 and 2011.61 It is important to note that 
the placenta tissue should not be viewed as a surrogate (to the brain) but a target tissue in 
understanding the genes-environment interplay. The placenta develops from the extra-
embryonic cell layer of the blastocyst, as opposed to the embryonic cell mass that will 
differentiate into the fetus.  In an effort to understand the mechanisms of how the environment 
gets “under the skin,” attention has been focused on the potential importance of the link 
between the placenta and fetal/child brain development. 
 
The placenta has been shown to produce an array of neuropeptide hormones that are 
analogues to those produced by the hypothalamus and the pituitary gland including GnRH, TRH, 
CRH, and oxytocin.62 Rapid advancements in the discovery of integrated regulation of 
neuropeptide homeostasis within the brain and placenta63, 64 has led to the concept that the 
placenta acts as a “third brain” linking the developed (maternal) and developing (fetal) brains.64, 
65 Maternal perturbations are conveyed to the fetus via the placenta, in the expression of 
transporters that regulate the flux of glucose, amino acids, and vitamins required for growth 
and development.12 Thus, the placenta serves as the “master regulator” in utero and plays a 
highly functional role in shaping fetal development.65  
 
Imprinted Genes Expressed in the Placenta and Fetoplacental Development: Fetoplacental 
development begins with a complex and highly coordinated set of epigenetic events that take 
place few hours after fertilization and before the implantation of the fertilized egg.12, 66, 67 
During this relatively short but very active window an almost complete reprogramming of the 
genome methylation takes place accompanied by a reorganization of the histone coding.67, 68 
Other, less characterized, 
epigenetic events also contribute 
to preparing the newly fused 
parental genomes for 
implantation and 
embryogenesis.67 At this stage 
specific genomic regions carrying 
a unique set of multilayer 
epigenetic signals inherited from 
the germline, known as 
Imprinting Control Regions (ICRs), 
are spared this epigenome 
 
Figure 1. Fetal imprinting reprogramming of DNA methylation marks during the early 
zygote developmental phases. F0 sperm and egg carry global (red and blue lines) and 
imprinting specific methylation signals (pink and light blue). After fertilization global 
methylation is reprogrammed at the blastocyst stadium. Imprinting signals are 
maintained unaltered to generate an embryo with distinct parental contributions. 
Imprinting reprogramming takes place only in the primordial germ cells later in 
development to generate gametes carrying imprinting marks according to the sex of the 
developing embryo. Perturbations of the imprinting profiles at the blastocyst stage can 
directly affect the embryo and also the gametes (F1 & F2 windows). Somatic cells 
separately develop from the embryo carrying the parental imprinting signals and the 
newly reprogrammed global methylation setting (purple line). They later rearrange their 
methylation status coherently with the adult tissue they will originate (green, orange, 
and brown lines) [Adapted from Lambertini et al., 201212] 
 
 
reprogramming wave (Figure 1).12, 69 ICRs control the allele-specific expression of clusters of 
about 200 genes (or about 1% of the protein-coding genes) distributed across the human 
genome. Genes which are monoallelically expressed through the action of these ICRs are known 
as imprinted genes with their expressed allele determined by the parent of origin. Imprinted 
genes are thus physically present as two copies but functionally haploid with about 50% of 
them maternally expressed and 50% paternally expressed.69-71 
 
A number of imprinted genes play critical roles in regulating the fetoplacental growth 
and development and instructing postnatal development. 13, 72 Based on their functional roles, 
imprinted genes have been classified in four main categories: 1) Genes that directly regulate 
fetal growth; 2) Genes that indirectly regulate fetal growth by modifying the function of the 
placenta; 3) Genes that modulate metabolic processes postnatally and 4) Genes that modify 
behavior postnatally. 13, 72, 73  
 
Furthermore, recent research suggests that a subset of imprinted genes expressed in 
the placenta may regulate maternal adaptations to pregnancy i.e. controlling the function of 
the mother, by regulating the production of placental hormones. 74 The timely expression of 
imprinted genes has been shown to play an important role in fetoplacental development.13, 75, 76  
These findings are in agreement with the functional importance of imprinted genes which, as 
shown for other such genes,77, 78 once altered, can lead to serious phenotypic consequences,79, 
80 some being lethal,81, 82 which may be further enhanced by the constitutional haplo-
insufficiency of imprinted genes.83  
 
The endurance of ICRs in the face of extensive epigenetic reprogramming early in 
development and through the life course raises many interesting points. As the ICR epigenetic 
setup is not reprogrammed at fertilization, it represents one of the few known instances of 
epigenetic inheritance.84 This in turn may explain the influence of the both parental 
environments prior to conception in determining fetal development. Environmentally-driven 
alterations of the ICR epigenetic status in the parents’ gametes at different stages of life may be 
preserved. Similarly, environmental exposure may influence the process that protects ICRs from 
the epigenome reprogramming wave happening at fertilization. As both types of exposure 
occur very early, the consequences are likely to be wide-ranging impacting the whole embryo 
and potentially detectable in most tissues.85, 86 Environmental exposures occurring after 
implantation that alter the ICR epigenetic setup or function also carry the potential for 
modifying the fetoplacental development trajectory at different stages.68, 87-89 Lastly it must be 
mentioned that the effects of the alteration of the ICR epigenetic setup can extend beyond the 
F1 generation. Primordial germ cells (PGCs) are the only embryonic cells that actually undergo 
ICR reprogramming in order to generate gametes that carry the ICR epigenetic setup specific to 
the sex of the developing embryo.12 Alterations that affect the process of erasure, 
reestablishment or maintenance during maturation into gametes could be passed to the F2 
generation. To summarize, the epigenetic setup of ICRs can be considered as a recording 
devices of past exposures 4 acting as lasting environmental biosensors of the intrauterine status 
as conveyed by the mother (e.g., changes in blood pressure). Of note, alterations of both the 
ICR epigenetic setup and imprinted genes have been linked to different pregnancy and 
newborn outcomes.87, 90-97 
 
Imprinted Genes as a Sensor of Pregnancy-Induced Hypertensive Disorder and Predictor of 
Child Development: Imprinted genes have been found to respond to common environmental 
stimuli. For example, peri-conceptional and prenatal exposure to both insufficient and 
excessive maternal nutrient intake have been found to leave lasting signals on the methylation 
profile of several imprinted domains, including imprinted genes INS, IGF2, GNASAS and MEG3.65 
 
Previous studies have examined the expression of imprinted genes in the placenta from 
preeclamptic pregnancies, often with conflicting results. For example, the maternally expressed 
imprinted gene CYCLIN-DEPENDENT KINASE INHIBITOR 1C (CDKN1C) has variously been 
reported to be significantly decreased,98 increased 99, 100 or unaltered 101 in preeclamptic 
placentas. These conflicting results may be explained by a difference in mode of delivery, given 
recent evidence demonstrating significantly increased CDKN1C expression in laboring versus 
non-laboring placentas. 102 Some mothers carrying babies with loss-of-function of CDKN1C have 
a very severe form of preeclamspia called HELLP (Hemolysis, Elevated Liver enzymes, Low 
platelet count) syndrome which is a life threatening complication. 103 There is data from an 
animal model to suggest loss-of-function of CDKN1C in the placenta may contribute to 
preeclampsia-like symptoms in the mother. Genetically unaltered female mice carrying Cdkn1c 
loss-of-function fetuses exhibit increased blood pressure and proteinurea during pregnancy. 104 
However, in a separate study, maternal symptoms where less apparent initially suggesting an 
environmental component. 105 Loss-of-function of Cdkn1c in the mouse placenta was associated 
with increased trophoblast proliferation and a narrowed intervillous space in some studies. 104, 
106 A narrowed intervillous space could impede uteroplacental blood flow, which combined 
with the shallow trophoblast invasion observed, could contribute to the development of 
preeclampsia-like symptoms. 104 However, a more recent study revealed a very different 
placental phenotype with a severely disorganized placenta late in gestation, and with maternal 
blood hemorrhaging into the blood spaces suggesting that genetic background could influence 
the phenotypic consequences of loss-of-function of Cdkn1c. 107 Taken together, these studies 
highlight the importance of further research investigating the relationship between 
preeclampsia and CDKN1C. 
 
A second imprinted gene, PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER 2 
(PHLDA2) has also been linked to preeclampsia. PHLDA2 was found to be highly overexpressed 
in placentas from preeclamptic pregnancies.108 The phenotype of female mice carrying fetuses 
with loss-of-function of Phlda2 has not been reported but overexpression of PHLDA2 in a 
human placental cell line resulted in impaired cell proliferation, migration and invasion.108 
Placental PHLDA2 expression may also be important in preeclampsia.  
 
  Around 70% of the known imprinted genes are expressed in the placenta 91 and recent 
work has demonstrated that alterations in placental imprinted gene expression are associated 
with infant neurodevelopmental outcomes.109 In two small pilot studies on 50 placenta samples 
from the Stress in Pregnancy (SIP) Study, we found both an alteration of the methylation profile 
of the ICR that regulates the parent-of-origin specific expression of two key imprinted genes, 
IGF2 and H19 (imprinted in the opposite direction) in correlation with maternal stress in 
pregnancy and an alteration of the global DNA methylation in correlation with preeclampsia.72 
We also found that imprinted gene expression in the placenta correlates with fetal growth and 
development, as measured by head circumference and birth weight.88, 109 Furthermore, the 
imprinting status of each imprinted locus, as defined by the ICR methylation status, has been 
shown to exert different effects on the reactivation of the silent allele of imprinted genes at 
that specific locus.91, 109 
 
Understanding the molecular mechanisms for fetal programming, through exposure to 
pregnancy-related medical problems, such as preeclampsia and pregnancy-induced 
hypertension, is a promising, but neglected, area of research while as a whole, the area of fetal 
programming represents an important first step towards prevention of lifelong negative 
developmental and mental health consequences for offspring. To achieve this, epigenetically 
informative longitudinal research that follows a birth cohort from a period in utero through 
childhood is the key to understanding how maternal preeclampsia in utero can influence an 
infant’s developmental trajectory by increasing vulnerability to cognitive and neurobehavioral 
impairment. If imprinting gene profiles are determined to be early biomarkers for impaired 
cognitive-neurobehavioral development, they could be used as biomarkers to design more 
targeted preventive measures for childhood developmental problems by alleviating and 
reducing the risk for maternal preeclampsia during pregnancy.   
 
In sum, gaining further understanding regarding the ways in which common pregnancy-
induced problems such as preeclampsia may lead to suboptimal fetal/infant development, 
specifically impaired neurobehavioral development via dysregulation in genomic imprinting 
status in the placenta, may yield effective clues for the prevention of neurodevelopmental 
disorders in early childhood. Prenatal influence caused by preeclampsia or hypertensive 
disorders will not fully explain the cause of the neurodevelopmental problems, as there are also 
many postnatal assaults that influence the risk for neurodevelopmental disorders in offspring, 
as well as other possible prenatal mechanism.  However, if epigenetic pathways can be used as 
potential tools for identifying high-risk infants, it is the first step toward developing prevention 
plans for full-fledged disorders later in childhood, perhaps though educating pregnant mothers.  
To this end, it is important to encourage collaboration among obstetricians, pediatricians, child 
psychiatrists, as well as early childhood educators to encourage research around the peri- and 
prenatal periods to reduce the risk for impaired neurodevelopmental disorders in childhood. 
Knowledge gained from such studies could contribute to an enhanced capacity for early 
prevention. At the same time, it will help inform and educate pregnant mothers about the 
importance of prenatal monitoring of blood pressure, weight gain, and metabolic functioning 
during pregnancy for the health of their offspring. 
 
References 
1. McCalla, C. O., Nacharaju, V. L., Muneyyirci-Delale, O., Glasgow, S., & Feldman, J. G. (1998). 
Placental 11β-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic 
pregnancies. Steroids, 63, 511-5. doi: 10.1016/s0039-128x(98)00056-7. 
2. Williams, M. A., Miller, R. S., Qiu, C., Cripe, S. M., Gelaye, B., & Enquobahrie, D. (2010). 
Associations of early pregnancy sleep duration with trimester-specific blood pressures and 
hypertensive disorders in pregnancy. Sleep, 33, 1363-71. PubMed PMID: 21061859; 
PMCID: 2941423. 
3. Podymow, T., & August, P. (2007). Hypertension in pregnancy. Adv Chronic Kidney Dis, 14, 
178-90. doi: 10.1053/j.ackd.2007.01.008. PubMed PMID: 17395120. 
4. Chang, J., Elam-Evans, L. D., Berg, C. J., Herndon, J., Flowers, L., Seed, K. A., & Syverson, C. J. 
(2003). Pregnancy-related mortality surveillance--United States, 1991--1999. Morbidity and 
Mortality Weekly Report Surveillance Summaries, 52, 1-8. PubMed PMID: 12825542. 
5. Saadat, M., Nejad, S. M., Habibi, G., & Sheikhvatan, M. (2007). Maternal and neonatal 
outcomes in women with preeclampsia. Taiwanese Journal of Obstetrics & Gynecology, 46, 
255-9. doi: 10.1016/S1028-4559(08)60029-7. PubMed PMID: 17962105. 
6. Getahun, D., Rhoads, G. G., Demissie, K., Lu, S. E., Quinn, V. P., Fassett, M. J., Wing, D. A., & 
Jacobsen, S. J. (2013). In utero exposure to ischemic-hypoxic conditions and attention-
deficit/hyperactivity disorder. Pediatrics, 131. doi: 10.1542/peds.2012-1298. PubMed 
PMID: 23230063. 
7. Mann, J. R., & McDermott, S. (2011). Are maternal genitourinary infection and pre-
eclampsia associated with ADHD in school-aged children? Journal of attention disorders, 
15, 667-73. doi: 10.1177/1087054710370566. PubMed PMID: 20837984. 
8. Silva, D., Colvin, L., Hagemann, E., & Bower, C. (2014). Environmental risk factors by gender 
associated with attention-deficit/hyperactivity disorder. Pediatrics, 133. doi: 
10.1542/peds.2013-1434. PubMed PMID: 24298003. 
9. Whitehouse, A. J., Robinson, M., Newnham, J. P., & Pennell, C. E. (2012). Do hypertensive 
diseases of pregnancy disrupt neurocognitive development in offspring? Paediatr Perinat 
Epidemiol, 26, 101-8. doi: 10.1111/j.1365-3016.2011.01257.x. PubMed PMID: 22324495. 
10. Nomura, Y., Marks, D. J., Grossman, B., Yoon, M., Loudon, H., Stone, J., & Halperin, J. M. 
(2012). Exposure to gestational diabetes mellitus and low socioeconomic status: effects on 
neurocognitive development and risk of attention-deficit/hyperactivity disorder in 
offspring. Archives of Pediatrics & Adolescent Medicine, 166, 337-43. doi: 
10.1001/archpediatrics.2011.784. PubMed PMID: 22213602. 
11. Ornoy, A., Ratzon, N., Greenbaum, C., Wolf, A., & Dulitzky, M. (2001). School-age children 
born to diabetic mothers and to mothers with gestational diabetes exhibit a high rate of 
inattention and fine and gross motor impairment. Journal of Pediatric Endocrinology and 
Metabolism, 14. doi: 10.1515/jpem.2001.14.s1.681. 
12. Lambertini, L., Lee, M-J, Marsit, J. C., Chen, J. (2012). Genomic imprinting in human 
placenta. Recent Advances in Research on the Human Placenta: InTech. 
13. Bressan, F. F., De Bem, T. H. C., Perecin, F., Lopes, F. L., Ambrosio, C. E., Meirelles, F. V., & 
Miglino, M. A. (2009). Unearthing the roles of imprinted genes in the placenta. Placenta, 
30, 823-34. doi: 10.1016/j.placenta.2009.07.007. 
14. Davies, W., Isles, A. R., & Wilkinson, L. S. (2005). Imprinted gene expression in the brain. 
Neuroscience & Biobehavioral Reviews, 29, 421-30. doi: 10.1016/j.neubiorev.2004.11.007. 
15. Davies, W., Isles, A. R., & Wilkinson, L. S. (2005). Imprinted gene expression in the brain. 
Neuroscience & Biobehavioral Reviews, 29, 421-30. doi: 10.1002/ajmg.b.30729. 
16. Roseboom, T., de Rooij, S., & Painter, R. (2006). The Dutch famine and its long-term 
consequences for adult health. Early Human Development, 82, 485-91. doi: 
10.1016/j.earlhumdev.2006.07.001. 
17. Susser, E,. Hoek, H. W., & Brown, A. (1998). Neurodevelopmental disorders after prenatal 
famine: the story of the Dutch Famine Study. American Journal of Epidemiology, 147, 213-
6. doi: 10.1093/oxfordjournals.aje.a009439. 
18. Rasmussen, S., & Irgens, L. M. (2003). Fetal growth and body proportion in preeclampsia. 
Obstet Gynecol, 101, 575-83. PubMed PMID: 12636965. 
19. Powe, C. E, Ecker, J., Rana, S., Wang, A., Ankers, E., Ye, J., Levine, R. J., Karumanchi, S. A., & 
Thadhani, R. (2011). Preeclampsia and the risk of large-for-gestational-age infants. Am J 
Obstet Gynecol, 204, 425 e1-6. doi: 10.1016/j.ajog.2010.12.030. PubMed PMID: 21371687. 
20. Bramham, K., Briley, A. L., Seed, P., Poston, L., Shennan, A. H., & Chappell, L. C. (2011). 
Adverse maternal and perinatal outcomes in women with previous preeclampsia: a 
prospective study. Am J Obstet Gynecol, 204, 512 e1-9. doi: 10.1016/j.ajog.2011.02.014. 
PubMed PMID: 21457915; PMCID: 3121955. 
21. Habli, M., Levine, R. J., Qian, C., & Sibai, B. (2007). Neonatal outcomes in pregnancies with 
preeclampsia or gestational hypertension and in normotensive pregnancies that delivered 
at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol, 197, 406 e1-7. doi: 
10.1016/j.ajog.2007.06.059. PubMed PMID: 17904980. 
22. Jelin, A. C, Cheng, Y. W., Shaffer, B. L., Kaimal, A. J., Little, S. E., & Caughey, A. B. (2010). 
Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med, 23, 389-
92. doi: 10.1080/14767050903168416. PubMed PMID: 19670045. 
23. Liggins, G. C., & Howie, R. N. (1972). A controlled trial of antepartum glucocorticoid 
treatment for prevention of the respiratory distress syndrome in premature infants. 
Pediatrics, 50, 515-25. PubMed PMID: 4561295. 
24. Odegard, R. A., Vatten, L. J, Nilsen, S. T., Salvesen, K. A., & Austgulen, R. (2000). 
Preeclampsia and fetal growth. Obstetrics and Gynecology, 96, 950-5. PubMed PMID: 
11084184. 
25. Swank, M., Nageotte, M., & Hatfield, T. (2012). Necrotizing pancreatitis associated with 
severe preeclampsia. Obstet Gynecol, 120, 453-5. doi: 10.1097/AOG.0b013e31824fc617. 
PubMed PMID: 22825263. 
26. Benediktsson, R., Lindsay, R. S., Noble, J., Seckl, J. R., & Edwards, C. R. (1993). 
Glucocorticoid exposure in utero: new model for adult hypertension. Lancet, 341, 339-41. 
PubMed PMID: Medline:8094115. 
27. Edwards, C. R., Benediktsson, R., Lindsay, R. S., & Seckl, J. R. (1993). Dysfunction of 
placental glucocorticoid barrier: link between fetal environment and adult hypertension? 
Lancet, 341, 355-7. PubMed PMID: 8094124. 
28. Kalder, M., Ulrich, S., Hitschold, T., & Berle, P. (1995). [Fetal development in mild and 
severe pre-eclampsia: correlation with maternal laboratory parameters and Doppler 
ultrasound]. Zeitschrift fur Geburtshilfe und Neonatologie, 199, 13-7. PubMed PMID: 
7725764. 
29. Liu, C. M., Cheng, P. J., & Chang, S. D. (2008). Maternal complications and perinatal 
outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese 
women. J Formos Med Assoc, 107, 129-38. doi: 10.1016/S0929-6646(08)60126-6. PubMed 
PMID: 18285245. 
30. Leuner, B., & Gould, E. (2010). Structural plasticity and hippocampal function. Annu Rev 
Psychol, 61, 111-40. doi: 10.1146/annurev.psych.093008.100359. 
31. Jones, B. P., Bell, E. A., & Maroof, M. (1999). Epidural labor analgesia in a parturient with 
von Willebrand's disease type IIA and severe preeclampsia. Anesthesiology, 90, 1219-20. 
PubMed PMID: 10201701. 
32. Masoura, S., Kalogiannidis, I., Margioula-Siarkou, C., Diamanti, E., Papouli, M., Drossou-
Agakidou, V., Prapas, N., & Agorastos, T. (2012). Neonatal outcomes of late preterm 
deliveries with pre-eclampsia. Minerva Ginecologica, 64, 109-15. PubMed PMID: 
22481621. 
33. Nomura, Y., Lambertini, L., Rialdi, A., Lee, M., Mystal, E. Y., Grabie, M., Manaster, I., Huynh, 
N., Finik, J., Davey, M., Davey, K., Ly, J., Stone, J., Loudon, H., Eglinton, G., Hurd, Y., 
Newcorn, J.H., & Chen, J. (2013). Global methylation in the placenta and umbilical cord 
blood from pregnancies with maternal gestational diabetes, preeclampsia, and obesity. 
Reproductive Sciences, 21, 131-7. doi: 10.1177/1933719113492206. 
34. Bos, A. F., Einspieler, C., Prechtl, H. F. R. (2001). Intrauterine growth retardation, general 
movements, and neurodevelopmental outcome: a review. Dev Med Child Neurol, 43, 61-
68. doi: 10.1017/s001216220100010x. 
35. Tolsa, C. B., Zimine, S., Warfield, S. K., Freschi, M., Sancho Rossignol, A., Lazeyras, F., 
Hanquinet, S., Pfizenmaier, M., & Huppi, P. S. (2004). Early alteration of structural and 
functional brain development in premature infants born with intrauterine growth 
restriction. Pediatr Res, 56, 132-8. doi: 10.1203/01.PDR.0000128983.54614.7E. PubMed 
PMID: 15128927. 
36. Bos, A. F., Einspieler, C., & Prechtl, H.F. (2001). Intrauterine growth retardation, general 
movements, and neurodevelopmental outcome: a review. Dev Med Child Neurol, 43, 61-8. 
PubMed PMID: 11201426. 
37. Allin, M., Matsumoto, H., Santhouse, A. M., Nosarti, C., AlAsady, M. H., Stewart, A. L., 
Rifkin, L., & Murray, R. M. (2001). Cognitive and motor function and the size of the 
cerebellum in adolescents born very pre-term. Brain, 124, 60-6. PubMed PMID: 11133787. 
38. Marlow, N., Wolke, D., Bracewell, M. A., & Samara, M. (2005). Neurologic and 
developmental disability at six years of age after extremely preterm birth. The New 
England Journal of Medicine, 352, 9-19. doi: 10.1056/NEJMoa041367. PubMed PMID: 
15635108. 
39. Moster, D., Lie, R. T., & Markestad, T. (2008). Long-term medical and social consequences 
of preterm birth. The New England Journal of Medicine, 359, 262-73. doi: 
10.1056/NEJMoa0706475. PubMed PMID: 18635431. 
40. Straub, H., Adams, M., Kim, J. J., & Silver, R. K. (2012). Antenatal depressive symptoms 
increase the likelihood of preterm birth. Am J Obstet Gynecol, 207, 329 e1-4. doi: 
10.1016/j.ajog.2012.06.033. PubMed PMID: 22789523. 
41. Hack, M., Schluchter, M., Cartar, L., Rahman, M., Cuttler, L., & Borawski, E. (2003). Growth 
of very low birth weight infants to age 20 years. Pediatrics, 112, e30-8. PubMed PMID: 
12837903. 
42. Mikkola, K., Ritari, N., Tommiska, V., Salokorpi, T., Lehtonen, L., Tammela, O., Paakkonen, 
L., Olsen, P., Korkman, M., & Fellman, V. (2005). Neurodevelopmental outcome at 5 years 
of age of a national cohort of extremely low birth weight infants who were born in 1996-
1997. Pediatrics, 116, 1391-400. doi: 10.1542/peds.2005-0171. PubMed PMID: 16322163. 
43. Sung, I. K., Vohr, B., & Oh, W. (1993). Growth and neurodevelopmental outcome of very 
low birth weight infants with intrauterine growth retardation: comparison with control 
subjects matched by birth weight and gestational age. J Pediatr, 123, 618-24. PubMed 
PMID: 7692029. 
44. Davis, E. P., Glynn, L. M., Schetter, C. D., Hobel, C., Chicz-Demet, A., & Sandman, C. A. 
(2007). Prenatal exposure to maternal depression and cortisol influences infant 
temperament. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 
737-46. doi: 10.1097/chi.0b013e318047b775. PubMed PMID: 17513986. 
45. Huizink, A. C., Robles de Medina, P. G., Mulder, E. J., Visser, G. H., & Buitelaar, J. K. (2003). 
Stress during pregnancy is associated with developmental outcome in infancy. Journal of 
Child Psychology and Psychiatry, 44, 810-8. PubMed PMID: 12959490. 
46. Marcus, S., Lopez, J. F., McDonough, S., Mackenzie, M. J., Flynn, H., Neal, C. R., Jr., 
Gahagan, S., Volling, B., Kaciroti, N., & Vazquez, D. M. (2011). Depressive symptoms during 
pregnancy: impact on neuroendocrine and neonatal outcomes. Infant Behavior & 
Development, 34, 26-34. doi: 10.1016/j.infbeh.2010.07.002. PubMed PMID: 21035873; 
PMCID: 3053131. 
47. Many, A., Fattal, A., Leitner, Y., Kupferminc, M. J., Harel, S., Jaffa, A. (2003). 
Neurodevelopmental and cognitive assessment of children born growth restricted to 
mothers with and without preeclampsia. Hypertension in Pregnancy, 22, 25-9. doi: 
10.1081/PRG-120016791. PubMed PMID: 12648440. 
48. Cheng, S. W., Chou, H. C., Tsou, K. I., Fang, L. J., & Tsao, P. N. (2004). Delivery before 32 
weeks of gestation for maternal pre-eclampsia: neonatal outcome and 2-year 
developmental outcome. Early Human Development, 76, 39-46. doi: DOI 
10.1016/j.earthumdev.2003.10.004. PubMed PMID: WOS:000188509000004. 
49. Bayley, N. (2006). Bayley Scales of Infant and Toddler Development: Bayley-III. Harcourt 
Assessment ed. San Antonio: Psych. Corporation. 
50. Posner, M. I., Rothbart, M. K., Sheese, B. E., & Voelker, P. (2014). Developing Attention: 
Behavioral and Brain Mechanisms. Advances in Neuroscience, 2014, 1-9. doi: 
10.1155/2014/405094. 
51. Dougherty, L. R., Klein, D. N., Olino, T. M., Dyson, M., & Rose, S. (2009). Increased waking 
salivary cortisol and depression risk in preschoolers: the role of maternal history of 
melancholic depression and early child temperament. Journal of Child Psychology and 
Psychiatry, 50, 1495-503. doi: 10.1111/j.1469-7610.2009.02116.x. 
52. Madsen, K. S., Jernigan, T. L., Iversen, P., Frokjaer, V. G., Mortensen, E. L., Knudsen, G. M., 
& Baaré, W. F. C. (2012). Cortisol awakening response and negative emotionality linked to 
asymmetry in major limbic fibre bundle architecture. Psychiatry Research: Neuroimaging, 
201, 63-72. doi: 10.1016/j.pscychresns.2011.07.015. 
53. Whittle, S., Allen, N. B., Lubman, D. I., & Yücel, M. (2006). The neurobiological basis of 
temperament: Towards a better understanding of psychopathology. Neuroscience & 
Biobehavioral Reviews, 30, 511-25. doi: 10.1016/j.neubiorev.2005.09.003. 
54. Putnam, S. P., Gartstein, M. A., & Rothbart, M. K. (2006). Measurement of fine-grained 
aspects of toddler temperament: The Early Childhood Behavior Questionnaire. Infant 
Behavior and Development, 29, 386-401. doi: 10.1016/j.infbeh.2006.01.004. 
55. Barker, D. J. P. (1997). The fetal origins of coronary heart disease. Acta Paediatrica, 86, 78-
82. doi: 10.1111/j.1651-2227.1997.tb18351.x. 
56. Barker, D. J. P. (2004). The developmental origins of chronic adult disease. Acta 
Paediatrica, 93, 26-33. doi: 10.1111/j.1651-2227.2004.tb00236.x. 
57. Barker, D. J., & Godfrey, K. M. (2001). Fetal nutrition and cardiovascular disease in adult 
life. In Nutritional Health (pp. 253-268). Humana Press. 
58. Heijmans, B. T., Kremer, D., Tobi, E. W., Boomsma, D. I., & Slagboom, P. E. (2007). Heritable 
rather than age-related environmental and stochastic factors dominate variation in DNA 
methylation of the human IGF2/H19 locus. Human Molecular Genetics, 16, 547-54. doi: 
10.1093/hmg/ddm010. 
59. Boyle, C. A., Decoufle, P., & Yeargin-Allsopp, M. (1994). Prevalence and health impact of 
developmental disabilities in US children. Pediatrics, 93, 399-403. PubMed PMID: 7509480. 
60. Pastor, P. N., & Reuben, C. A. (2002). Attention Deficit Disorder and Learning Disability: 
United States, 1997-98. Vital and Health Statistics, Series 10, Number 206. American 
Psychological Association (APA). 
61. Baio, J. (2012). Prevalence of Autism Spectrum Disorders: Autism and Developmental 
Disabilities Monitoring Network, 14 Sites, United States, 2008. Morbidity and Mortality 
Weekly Report. Surveillance Summaries. Volume 61, Number 3. Centers for Disease Control 
and Prevention. 
62. Liu, J. H. (2009). Endocrinology of Pregnancy. Creasy and Resnik's Maternal-Fetal Medicine: 
Principles and Practice: Elsevier BV; p. 111-24. 
63. Petraglia, F., Coukos, G., Volpe, A., Genazzani, A. R., & Vale, W. (1991). Involvement of 
placental neurohormones in human parturition. Annals of the New York Academy of 
Sciences, 622, 331-40. doi: 10.1111/j.1749-6632.1991.tb37878.x. 
64. Yen, S. S. (1994). The placenta as the third brain. The Journal of Reproductive Medicine, 39, 
277-80. PubMed PMID: 8040844. 
65. Lambertini, L., Lee, T. L., Chan, W. Y., Lee, M. J., Diplas, A., Wetmur, J., & Chen, J. (2011). 
Differential methylation of imprinted genes in growth-restricted placentas. Reproductive 
Sciences, 18, 1111-7. doi: 10.1177/1933719111404611. 
66. Reik, W. (2001). Epigenetic reprogramming in mammalian development. Science, 293, 
1089-93. doi: 10.1126/science.1063443. 
67. Santos, F., & Dean, W. (2004). Epigenetic reprogramming during early development in 
mammals. Reproduction, 127, 643-51. doi: 10.1530/rep.1.00221. 
68. Perera, F., & Herbstman, J. (2011). Prenatal environmental exposures, epigenetics, and 
disease. Reproductive Toxicology, 31, 363-73. doi: 10.1016/j.reprotox.2010.12.055. 
69. DUJ. Geneimprint. The Genomic Imprinting Website. 
http://www.geneimprint.com/site/home2016. 
70. University O. Catalogue of Parent of Origin Effects 2016. Available from: 
http://igc.otago.ac.nz/home.html. 
71. Garg, P., Borel, C., & Sharp, A. J. (2012). Detection of parent-of-origin specific expression 
quantitative trait loci by cis-association analysis of gene expression in trios. PLoS ONE, 7, 
e41695. doi: 10.1371/journal.pone.0041695. 
72. Charalambous, M., da Rocha, S. T., & Ferguson-Smith, A. C. (2007). Genomic imprinting, 
growth control and the allocation of nutritional resources: consequences for postnatal life. 
Current Opinion in Endocrinology, Diabetes and Obesity, 14, 3-12. doi: 
10.1097/med.0b013e328013daa2. 
73. Shaikh, M. G. (2011). 2.4.1 Hypothalamic dysfunction (hypothalamic syndromes). In Wass, 
J. A., & Stewart, P. M. (Eds.), Oxford Textbook of Endocrinology and Diabetes (pp. 233-
240) New York: Oxford University Press (OUP). 
74. John, R. M. (2013). Epigenetic regulation of placental endocrine lineages and complications 
of pregnancy. Biochemical Society Transactions, 41, 701-9. doi: 10.1042/BST20130002. 
PubMed PMID: 23697929. 
75. McMinn, J., Wei, M., Schupf, N., Cusmai, J., Johnson, E. B., Smith, A. C., Weksberg, R., 
Thaker, H. M., & Tycko, B. (2006). Unbalanced placental expression of imprinted genes in 
human intrauterine growth restriction. Placenta, 27, 540-9. doi: 
10.1016/j.placenta.2005.07.004. 
76. Tycko, B., & Morison, I. M. (2002). Physiological functions of imprinted genes. J Cell Physiol, 
192, 245-58. doi: 10.1002/jcp.10129. 
77. Newman, J. R. S., Ghaemmaghami, S., Ihmels, J., Breslow, D. K., Noble, M., DeRisi, J. L., & 
Weissman, J. S. (2006). Single-cell proteomic analysis of S. cerevisiae reveals the 
architecture of biological noise. Nature, 441, 840-6. doi: 10.1038/nature04785. 
78. Zaitoun, I., Downs, K. M., Rosa, G. J. M., & Khatib, H. (2010). Upregulation of imprinted 
genes in mice: An insight into the intensity of gene expression and the evolution of 
genomic imprinting. Epigenetics, 5, 149-58. doi: 10.4161/epi.5.2.11081. 
79. Elowitz, M. B. (2002). Stochastic gene expression in a single cell. Science, 297, 1183-6. doi: 
10.1126/science.1070919. 
80. Ozbudak, E. M., Thattai, M., Kurtser, I., Grossman, A. D., & van Oudenaarden, A. (2002). 
Regulation of noise in the expression of a single gene. Nature Genetics, 31, 69-73. doi: 
10.1038/ng869. 
81. Blake, W. J., KÆrn, M., Cantor, C. R., & Collins, J. J. (2003). Noise in eukaryotic gene 
expression. Nature, 422, 633-7. doi: 10.1038/nature01546. 
82. Fraser, H. B., Hirsh, A. E., Giaever, G., Kumm, J., & Eisen, M. B. (2004). Noise minimization 
in eukaryotic gene expression. PLoS Biology, 2, e137. doi: 10.1371/journal.pbio.0020137. 
83. Batada, N. N., & Hurst, L. D. (2007). Evolution of chromosome organization driven by 
selection for reduced gene expression noise. Nature Genetics, 39, 945-9. doi: 
10.1038/ng2071. 
84. Guerrero-Bosagna, C., & Skinner, M. K. (2012). Environmentally induced epigenetic 
transgenerational inheritance of phenotype and disease. Molecular and Cellular 
Endocrinology, 354, 3-8. doi: 10.1016/j.mce.2011.10.004. 
85. Dolinoy, D. C., & Jirtle, R. L. (2008). Environmental epigenomics in human health and 
disease. Environmental and Molecular Mutagenesis, 49, 4-8. doi: 10.1002/em.20366. 
86. Wolff, M. S., Engel, S., Berkowitz, G., Teitelbaum, S., Siskind, J., Barr, D. B., & Wetmur, J. 
(2007). Prenatal pesticide and pcb exposures and birth outcomes. Pediatr Res, 61, 243-50. 
doi: 10.1203/pdr.0b013e31802d77f0. 
87. Jirtle, R. L., & Skinner, M. K. (2007). Environmental epigenomics and disease susceptibility. 
Nat Rev Genet, 8, 253-62. doi: 10.1038/nrg2045. 
88. Kappil, M., Lambertini, L., & Chen, J. (2015). Environmental influences on genomic 
imprinting. Current Environmental Health Reports, 2, 155-62. doi: 10.1007/s40572-015-
0046-z. 
89. Lambertini, L. (2014). Genomic imprinting. Current Opinion in Pediatrics, 26, 237-42. doi: 
10.1097/mop.0000000000000072. 
90. Chen, J., Li, Q., Rialdi, A., Mystal, E. Y., Ly, J., Finik, J., Davey, T., Lambertini, L., & Nomura, Y. 
(2014). Influences of maternal stress during pregnancy on the epi/genome: Comparison of 
placenta and umbilical cord blood. Depress Anxiety, 3, 1-6. 
91. Diplas, A. I., Lambertini, L., Lee, M-J, Sperling, R., Lee, Y. L., Wetmur, J. G., & Chen, J. (2009). 
Differential expression of imprinted genes in normal and IUGR human placentas. 
Epigenetics, 4, 235-40. doi: 10.4161/epi.9019. 
92. Green, B. B., Kappil, M., Lambertini, L., Armstrong, D. A., Guerin, D. J., Sharp, A. J., Lester, B. 
M., Chen, J., & Marsit, C. J. (2015). Expression of imprinted genes in placenta is associated 
with infant neurobehavioral development. Epigenetics, 10, 834-41. doi: 
10.1080/15592294.2015.1073880. 
93. Lambertini, L., Diplas, A.I., Lee, M-J, Sperling, R., Chen, J., Wetmur, J. G. (2008). A sensitive 
functional assay reveals frequent loss of genomic imprinting in human placenta. 
Epigenetics, 3, 261-9. doi: 10.4161/epi.3.5.6755. 
94. Lambertini, L., Diplas, A. L., Wetmur, J., Lee, M. J., & Chen, J. (2009). Evaluation of genomic 
imprinting employing the analysis of Loss of Imprinting (LOI) at the RNA level: preliminary 
results. Eur J Oncol, 14, 161-9. 
95. Lambertini, L., Marsit, C. J., Sharma, P., Maccani, M., Ma, Y., Hu, J., & Chen, J. (2012). 
Imprinted gene expression in fetal growth and development. Placenta, 33, 480-6. doi: 
10.1016/j.placenta.2012.03.001. 
96. Marsit,  C. J., Lambertini, L., Maccani, M. A., Koestler, D. C., Houseman, E. A., Padbury, J. F., 
Lester, B. M., & Chen, J. (2012). Placenta-imprinted gene expression association of infant 
neurobehavior. J Pediatr, 160, 854-60 e2. doi: 10.1016/j.jpeds.2011.10.028. PubMed PMID: 
22153677; PMCID: 3311768. 
97. Mathers, J. C. (2007). Early nutrition: Impact on Epigenetics. Nutrigenomics - Opportunities 
in Asia: S. Karger AG, 42-8. 
98. Kawasaki, K., Kondoh, E., Chigusa, Y., Ujita, M., Murakami, R., Mogami, H., Brown, J. B., 
Okuno, Y., & Konishi, I. (2015). Reliable pre-eclampsia pathways based on multiple 
independent microarray data sets. Molecular Human Reproduction, 1, 217-24. doi: 
10.1093/molehr/gau096. PubMed PMID: 25323968. 
99. Enquobahrie, D. A., Meller, M., Rice, K., Psaty, B. M., Siscovick, D. S., & Williams, M. A. 
(2008). Differential placental gene expression in preeclampsia. Am J Obstet Gynecol, 199, 
566 e1-11. doi: 10.1016/j.ajog.2008.04.020. PubMed PMID: 18533121; PMCID: 2702488. 
100. Unek, G., Ozmen, A., Mendilcioglu, I., Simsek, M., & Korgun, E. T. (2014). The expression of 
cell cycle related proteins PCNA, Ki67, p27 and p57 in normal and preeclamptic human 
placentas. Tissue & Cell, 46, 198-205. doi: 10.1016/j.tice.2014.04.003. PubMed PMID: 
24852133. 
101. Bourque, D. K., Avila, L., Penaherrera, M., von Dadelszen, P., & Robinson, W. P. (2010). 
Decreased placental methylation at the H19/IGF2 imprinting control region is associated 
with normotensive intrauterine growth restriction but not preeclampsia. Placenta, 31, 197-
202. doi: 10.1016/j.placenta.2009.12.003. PubMed PMID: 20060582. 
102. Janssen, A. B., Tunster, S. J., Savory, N., Holmes, A., Beasley, J., Parveen, S. A., Penketh, R. 
J., & John, R. M. (2015). Placental expression of imprinted genes varies with sampling site 
and mode of delivery. Placenta, 36, 790-5. doi: 10.1016/j.placenta.2015.06.011. PubMed 
PMID: 26162698; PMCID: 4535278. 
103. Romanelli, V., Belinchon, A., Campos-Barros, A., Heath, K. E., Garcia-Minaur, S., Martinez-
Glez, V., Palomo, R., Mercado, G., Gracia, R., & Lapunzina, P. (2009). CDKN1C mutations in 
HELLP/preeclamptic mothers of Beckwith-Wiedemann Syndrome (BWS) patients. Placenta, 
30, 551-4. doi: 10.1016/j.placenta.2009.03.013. PubMed PMID: 19386358. 
104. Kanayama, N., Takahashi, K., Matsuura, T., Sugimura, M., Kobayashi, T., Moniwa, N., 
Tomita, M., & Nakayama, K. (2002). Deficiency in p57Kip2 expression induces 
preeclampsia-like symptoms in mice. Molecular Human Reproduction, 8, 1129-35. PubMed 
PMID: 12468647. 
105. Knox, K. S., & Baker, J. C. (2007). Genome-wide expression profiling of placentas in the 
p57Kip2 model of pre-eclampsia. Molecular Human Reproduction, 13, 251-63. doi: 
10.1093/molehr/gal116. PubMed PMID: 17289831. 
106. Takahashi, K., Kobayashi, T., & Kanayama, N. (2000). p57(Kip2) regulates the proper 
development of labyrinthine and spongiotrophoblasts. Molecular Human Reproduction, 6, 
1019-25. PubMed PMID: 11044465. 
107. Tunster, S. J., Van de Pette, M., & John, R. M. (2011). Fetal overgrowth in the Cdkn1c 
mouse model of Beckwith-Wiedemann syndrome. Disease Models & Mechanisms, 4, 814-
21. doi: 10.1242/dmm.007328. PubMed PMID: 21729874; PMCID: 3209650. 
108. Jin, F., Qiao, C., Luan, N., Shang, T. (2015). The expression of the imprinted gene pleckstrin 
homology-like domain family A member 2 in placental tissues of preeclampsia and its 
effects on the proliferation, migration and invasion of trophoblast cells JEG-3. Clinical And 
Experimental Pharmacology & Physiology, 42, 1142-51. doi: 10.1111/1440-1681.12468. 
PubMed PMID: 26218012. 
109. Weksberg, R. (2010). Imprinted genes and human disease. Am J Med Genet, 154C, 317-20. 
doi: 10.1002/ajmg.c.30268. 
 
